Clinical Trial Update: Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial evaluating anecortave acetate for chronic central serous chorioretinopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Chronic Central Serous Chorioretinopathy | Phase 1, Phase 2 | Status: COMPLETED